BIOMAT Database Logo BIOMAT Database Logo

Clinical trial with subcutaneously administered 5-azacytidine (NSC-102816). 1974

R E Bellet, and M J Mastrangelo, and P F Engstrom, and J G Strawitz, and A J Weiss, and J W Yarbro

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D012075 Remission, Spontaneous A spontaneous diminution or abatement of a disease over time, without formal treatment. Spontaneous Healing,Spontaneous Regression,Spontaneous Remission,Healing, Spontaneous,Regression, Spontaneous,Spontaneous Healings,Spontaneous Regressions
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females

Related Publications

R E Bellet, and M J Mastrangelo, and P F Engstrom, and J G Strawitz, and A J Weiss, and J W Yarbro
Treatment of acute leukemia with 5-azacytidine (NSC-102816).
January 1973, Cancer chemotherapy reports,
R E Bellet, and M J Mastrangelo, and P F Engstrom, and J G Strawitz, and A J Weiss, and J W Yarbro
A phase I study of 5-azacytidine (NSC-102816).
April 1976, Journal of clinical pharmacology,
R E Bellet, and M J Mastrangelo, and P F Engstrom, and J G Strawitz, and A J Weiss, and J W Yarbro
Phase I study of twice weekly 5-azacytidine (NSC-102816).
January 1974, Cancer chemotherapy reports,
R E Bellet, and M J Mastrangelo, and P F Engstrom, and J G Strawitz, and A J Weiss, and J W Yarbro
Absorption, distribution, and excretion of 5-azacytidine (NSC-102816) in man.
June 1972, Cancer chemotherapy reports,
R E Bellet, and M J Mastrangelo, and P F Engstrom, and J G Strawitz, and A J Weiss, and J W Yarbro
Phase I study using combination of hydroxyurea and 5-azacytidine (NSC-102816).
January 1980, Neoplasma,
R E Bellet, and M J Mastrangelo, and P F Engstrom, and J G Strawitz, and A J Weiss, and J W Yarbro
5-Azacytidine (NSC 102816): a new drug for the treatment of myeloblastic leukemia.
September 1976, Blood,
R E Bellet, and M J Mastrangelo, and P F Engstrom, and J G Strawitz, and A J Weiss, and J W Yarbro
Combination therapy with 5-azacytidine (NSC-102816) and methyl-GAG (NSC-32946) in previously treated adults with acute nonlymphocytic leukemia.
January 1975, Cancer chemotherapy reports,
R E Bellet, and M J Mastrangelo, and P F Engstrom, and J G Strawitz, and A J Weiss, and J W Yarbro
Phase I study of 5-azacytidine (NSC-102816) using 24-hour continuous infusion for 5 days.
January 1975, Cancer chemotherapy reports,
R E Bellet, and M J Mastrangelo, and P F Engstrom, and J G Strawitz, and A J Weiss, and J W Yarbro
Enhancement by tetrahydrouridine (NSC-112907) of the oral activity of 5-azacytidine (NSC-102816) in L1210 leukemic mice.
January 1975, Cancer chemotherapy reports,
R E Bellet, and M J Mastrangelo, and P F Engstrom, and J G Strawitz, and A J Weiss, and J W Yarbro
5-Azacytidine (NSC 102816) in refractory germ cell tumors. A phase II trial of the Eastern Cooperative Oncology Group.
January 1993, Investigational new drugs,
Copied contents to your clipboard!